Join to access to all OVN content. Join for Free
The 2 Most Critical Elements of MSL Territory Excellence with Julie Montiel
MSL territory excellence scientific acumen virtual presentation skills strategic territory planning MSL performance improvement

The 2 Most Critical Elements of MSL Territory Excellence with Julie Montiel


Share This Article


Summary

In this episode, Tom Caravela is joined by Julie Montiel to explore the nuances of MSL territory excellence and the critical role of scientific acumen. They delve into strategies for achieving scientific acumen and crafting effective, individualized territory plans. The conversation highlights the significance of pre-call and post-call planning in managing territories, as well as adapting strategies for virtual and digital engagements. Julie shares tips to enhance virtual presentation skills, concluding with a recap on creating a plan for territory excellence. The episode wraps up with closing remarks on the importance of key MSL strategies and a call to action for listeners.

My guest today is Julie Montiel, the National Scientific Director, Lymphoma/Myeloid MSL at The Janssen. We talk about the two most critical of MSL territory excellence.

In this episode we discuss:

  • Julie’s background
  • The two most critical elements
  • How MSLs improve their performance
  • What is scientific acumen 
  • Why is scientific acumen the most important element of territory excellence
  • What does excellence in scientific acumen look like?
  • Every territory is different
  • Applying principles to a virtual type of scenario
  • How MSLs bring all of these pieces of information together to build strategic territory excellence

Click for Source
MSL territory excellence, scientific acumen, virtual presentation skills, strategic territory planning, MSL performance improvement

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
OVN Avatar Karen Geary

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Article
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
OVN Avatar J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Article
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer
OVN Avatar Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys

Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer

Explore OVN